These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 34652918)

  • 1. Development of BromoTag: A "Bump-and-Hole"-PROTAC System to Induce Potent, Rapid, and Selective Degradation of Tagged Target Proteins.
    Bond AG; Craigon C; Chan KH; Testa A; Karapetsas A; Fasimoye R; Macartney T; Blow JJ; Alessi DR; Ciulli A
    J Med Chem; 2021 Oct; 64(20):15477-15502. PubMed ID: 34652918
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-guided discovery of novel potent and efficacious proteolysis targeting chimera (PROTAC) degrader of BRD4.
    Xiang W; Wang Q; Ran K; Ren J; Shi Y; Yu L
    Bioorg Chem; 2021 Oct; 115():105238. PubMed ID: 34390970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Native Mass Spectrometry for the Study of PROTAC GNE-987-Containing Ternary Complexes.
    Sternicki LM; Nonomiya J; Liu M; Mulvihill MM; Quinn RJ
    ChemMedChem; 2021 Jul; 16(14):2206-2210. PubMed ID: 33792163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of novel small molecule induced selective degradation of the bromodomain and extra-terminal (BET) bromodomain protein BRD4 and BRD2 with cellular potencies.
    Jiang F; Wei Q; Li H; Li H; Cui Y; Ma Y; Chen H; Cao P; Lu T; Chen Y
    Bioorg Med Chem; 2020 Jan; 28(1):115181. PubMed ID: 31767403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of a selective BRD4 PROTAC with potent antiproliferative effects in AR-positive prostate cancer based on a dual BET/PLK1 inhibitor.
    Hu R; Wang WL; Yang YY; Hu XT; Wang QW; Zuo WQ; Xu Y; Feng Q; Wang NY
    Eur J Med Chem; 2022 Jan; 227():113922. PubMed ID: 34700270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of AID2 and BromoTag expands the utility of degron-based protein knockdowns.
    Hatoyama Y; Islam M; Bond AG; Hayashi KI; Ciulli A; Kanemaki MT
    EMBO Rep; 2024 Sep; 25(9):4062-4077. PubMed ID: 39179892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-Guided Design of a "Bump-and-Hole" Bromodomain-Based Degradation Tag.
    Nowak RP; Xiong Y; Kirmani N; Kalabathula J; Donovan KA; Eleuteri NA; Yuan JC; Fischer ES
    J Med Chem; 2021 Aug; 64(15):11637-11650. PubMed ID: 34279939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural basis of PROTAC cooperative recognition for selective protein degradation.
    Gadd MS; Testa A; Lucas X; Chan KH; Chen W; Lamont DJ; Zengerle M; Ciulli A
    Nat Chem Biol; 2017 May; 13(5):514-521. PubMed ID: 28288108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of photocontrolled BRD4 PROTACs for tongue squamous cell carcinoma (TSCC).
    Li Z; Ma S; Yang X; Zhang L; Liang D; Dong G; Du L; Lv Z; Li M
    Eur J Med Chem; 2021 Oct; 222():113608. PubMed ID: 34119833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Photo-regulated PROTACs: A novel tool for temporal control of targeted protein degradation.
    Xu H; Ohoka N; Inoue T; Yokoo H; Demizu Y
    Bioorg Med Chem Lett; 2024 Jul; 107():129778. PubMed ID: 38702019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody-PROTAC Conjugates Enable HER2-Dependent Targeted Protein Degradation of BRD4.
    Maneiro MA; Forte N; Shchepinova MM; Kounde CS; Chudasama V; Baker JR; Tate EW
    ACS Chem Biol; 2020 Jun; 15(6):1306-1312. PubMed ID: 32338867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of small-molecule BRD4 degraders based on pyrrolopyridone derivative.
    Zhang J; Chen P; Zhu P; Zheng P; Wang T; Wang L; Xu C; Zhou J; Zhang H
    Bioorg Chem; 2020 Jun; 99():103817. PubMed ID: 32361153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis, SAR, and application of JQ1 analogs as PROTACs for cancer therapy.
    De S; Sahu R; Palei S; Narayan Nanda L
    Bioorg Med Chem; 2024 Oct; 112():117875. PubMed ID: 39178586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protein targeting chimeric molecules specific for dual bromodomain 4 (BRD4) and Polo-like kinase 1 (PLK1) proteins in acute myeloid leukemia cells.
    Mu X; Bai L; Xu Y; Wang J; Lu H
    Biochem Biophys Res Commun; 2020 Jan; 521(4):833-839. PubMed ID: 31708096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of a Covalent FEM1B Recruiter for Targeted Protein Degradation Applications.
    Henning NJ; Manford AG; Spradlin JN; Brittain SM; Zhang E; McKenna JM; Tallarico JA; Schirle M; Rape M; Nomura DK
    J Am Chem Soc; 2022 Jan; 144(2):701-708. PubMed ID: 34994556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor-targeted PROTAC prodrug nanoplatform enables precise protein degradation and combination cancer therapy.
    Zou ZF; Yang L; Nie HJ; Gao J; Lei SM; Lai Y; Zhang F; Wagner E; Yu HJ; Chen XH; Xu ZA
    Acta Pharmacol Sin; 2024 Aug; 45(8):1740-1751. PubMed ID: 38609561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A small-molecule degron with a phenylpropionic acid scaffold.
    Tomoshige S; Komatsu F; Kikuchi T; Sugiyama M; Kawasaki Y; Ohgane K; Furuyama Y; Sato S; Ishikawa M; Kuramochi K
    Bioorg Med Chem; 2024 Jul; 109():117789. PubMed ID: 38870716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody-Mediated Delivery of Chimeric BRD4 Degraders. Part 2: Improvement of In Vitro Antiproliferation Activity and In Vivo Antitumor Efficacy.
    Dragovich PS; Pillow TH; Blake RA; Sadowsky JD; Adaligil E; Adhikari P; Chen J; Corr N; Dela Cruz-Chuh J; Del Rosario G; Fullerton A; Hartman SJ; Jiang F; Kaufman S; Kleinheinz T; Kozak KR; Liu L; Lu Y; Mulvihill MM; Murray JM; O'Donohue A; Rowntree RK; Sawyer WS; Staben LR; Wai J; Wang J; Wei B; Wei W; Xu Z; Yao H; Yu SF; Zhang D; Zhang H; Zhang S; Zhao Y; Zhou H; Zhu X
    J Med Chem; 2021 Mar; 64(5):2576-2607. PubMed ID: 33596073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alkenyl oxindole is a novel PROTAC moiety that recruits the CRL4DCAF11 E3 ubiquitin ligase complex for targeted protein degradation.
    Wang Y; Wei T; Zhao M; Huang A; Sun F; Chen L; Lin R; Xie Y; Zhang M; Xu S; Sun Z; Hong L; Wang R; Tian R; Li G
    PLoS Biol; 2024 May; 22(5):e3002550. PubMed ID: 38768083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiotherapy-Triggered Proteolysis Targeting Chimera Prodrug Activation in Tumors.
    Yang C; Yang Y; Li Y; Ni Q; Li J
    J Am Chem Soc; 2023 Jan; 145(1):385-391. PubMed ID: 36542856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.